Antidiabetic Drug Approved to Reduce Risk of Kidney Disease
- 1 September 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Nursing
- Vol. 121 (9), 25
- https://doi.org/10.1097/01.naj.0000790624.30479.00
Abstract
Dapagliflozin (Farxiga) is now approved to reduce the risk of declining kidney function, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease with or without type 2 diabetes.Keywords
This publication has 1 reference indexed in Scilit:
- Dapagliflozin in Patients with Chronic Kidney DiseaseThe New England Journal of Medicine, 2020